Recombinant human interferon alpha 2a is a protein indicated for the treatment of diseases such as hairy cell leukemia, multiple myeloma, non-Hodgkin’s lymphoma, chronic myeloid leukemia, chronic hepatitis B, acute and chronic hepatitis C and accumulated condyloma.
It is believed that this remedy works by inhibiting viral replication and modulating the immune response of the host, thus exerting an antitumor and antiviral activity.
- Recombinant human interferon alpha 2A should be administered by a healthcare professional.
- Who knows how to prepare the drug.
- The dose depends on the disease to be treated:.
The recommended daily dose of the drug is 3 MUI for 16 to 20 weeks, administered by intramuscular or subcutaneous injection.It may be necessary to reduce the dose or frequency of injections to determine the maximum tolerated dose.The recommended maintenance dose is 3 MUI, three times a week.
When side effects are severe, it may be necessary to halve the dose and your doctor should determine whether the person should continue treatment after six months of treatment.
The recommended dose of recombinant human interferon alfa 2A is 3 MUI, three times per week, administered by intramuscular or subcutaneous injection.Depending on the person’s response and tolerance, the dose may be gradually increased to 9 MUI, three times a week.
In people with non-Hodgkin’s lymphoma, the drug can be given 4 to 6 weeks after chemotherapy and the recommended dose is 3 MUI, three times a week for at least 12 weeks, subcutaneously.When administered in combination with chemotherapy, the recommended dose is 6 MUI/m2, administered subcutaneously or intramuscularly during days 22 to 26 of chemotherapy.
The recombinant human interferon alfa 2A dose may be progressively increased from 3 MUI per day for three days to 6 MUI per day for three days up to the target dose of 9 MUI per day until the end of the treatment period.patients with a haematological response may continue treatment until full response or 18 months to 2 years after initiation of treatment.
The recommended dose for adults is 5 MUI, three times a week, administered subcutaneously for 6 months.For people who do not respond to recombinant human interferon alpha 2A after one month of treatment, increased dose may be required.
If, after 3 months of treatment, there is no patient response, discontinuation of treatment should be considered.
The recommended dose of recombinant human interferon alfa 2A for treatment is 3 to 5 MUI, three times per week, administered subcutaneously or intramuscularly for 3 months.The recommended maintenance dose is 3 MUI, three times a week for 3 months.
The recommended dose is a subcutaneous or intramuscular application of 1 MUI to 3 MUI, 3 times a week, for 1 to 2 months or 1 MUI applied at the base of the affected site every other day, for 3 consecutive weeks.
This medicine should not be used in people with hypersensitivity to any of the components of the formula, disease or history of severe heart, kidney or liver disease.
In addition, it should not be used in pregnant or lactating women, except on the recommendation of the doctor.
The most common side effects that may occur when using this medicine are flu-like symptoms, such as fatigue, fever, chills, muscle aches, headaches, joint pains, sweating, among others.